1.6900
10-May-24 09:43:33
15 minutes delayed
Stocks
0.0000
0.00%
Today's range
1.6900 - 1.7200
ISIN
N/A
Source
NASDAQ
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
12 Jun 2023 09:15:00 By Nasdaq GlobeNewswire
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
01 Jun 2023 09:10:00 By Nasdaq GlobeNewswire